Your browser doesn't support javascript.
loading
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
Yang, Zheng; Rajendran, Surendran; Spires, Vanessa; Poirson, Brian; Gururajan, Murali; Lin, Zheng; Arbanas, Jaren; Krystek, Stanley; Loy, James; Cheng, Yuan; Carl, Stephen; Pace, Samantha; Wang, Yun; Mehl, John; Xu, Shihua; Vasudevan, Krishna; Broz, Miranda; Lehman-McKeeman, Lois; Morin, Paul; Graziano, Robert F.
Affiliation
  • Yang Z; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Rajendran S; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Spires V; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Poirson B; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Gururajan M; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Lin Z; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Arbanas J; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Krystek S; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Loy J; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Cheng Y; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Carl S; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Pace S; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Wang Y; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Mehl J; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Xu S; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Vasudevan K; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Broz M; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Lehman-McKeeman L; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Morin P; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
  • Graziano RF; Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization (Z.Y.), Nonclinical Disposition and Bioanalysis (S.R., S.X.), Discovery Biotherapeutics (Z.L., J.A., P.M.), Molecular Structure and Design (S.K.), Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimiza
Drug Metab Dispos ; 50(7): 898-908, 2022 07.
Article de En | MEDLINE | ID: mdl-35545256
ABSTRACT
Fragment crystallizable (Fc) fusion is commonly used for extending the half-life of biotherapeutics such as cytokines. In this work, we studied the pharmacokinetics of Fc-fused interleukin-10 (IL-10) proteins that exhibited potent antitumor activity in mouse syngeneic tumor models. At pharmacologically active doses of ≥0.1 mg/kg, both mouse Fc-mouse IL-10 and human Fc-human IL-10, constructed as the C terminus of the Fc domain fused with IL-10 via a glycine-serine polypeptide linker, exhibited nonlinear pharmacokinetics after intravenous administration to mice at the doses of 0.05, 0.5, and 5 mg/kg. With a nominal dose ratio of 110100; the ratio of the area under the curve for mouse Fc-mouse IL-10 and human Fc-human IL-10 was 11811830 and 175633, respectively. In contrast, recombinant mouse or human IL-10 proteins exhibited linear pharmacokinetics in mice. Compartmental analysis, using the Michaelis-Menten equation with the in vitro IL-10 receptor alpha binding affinity inputted as the Km, unified the pharmacokinetic data across the dose range. Additionally, nontarget-mediated clearance estimated for fusion proteins was ∼200-fold slower than that for cytokines, causing the manifestation of target-mediated drug disposition (TMDD) in the fusion protein pharmacokinetics. The experimental data generated with a mouse IL-10 receptor alpha-blocking antibody and a human Fc-human IL-10 mutant with a reduced receptor binding affinity showed significant improvements in pharmacokinetics, supporting TMDD as the cause of nonlinearity. Target expression and its effect on pharmacokinetics must be determined when considering using Fc as a half-life extension strategy, and pharmacokinetic evaluations need to be performed at a range of doses covering pharmacological activity. SIGNIFICANCE STATEMENT Target-mediated drug disposition can manifest to affect the pharmacokinetics of a fragment crystallizable (Fc)-fused cytokine when the nontarget-mediated clearance of the cytokine is decreased due to neonatal Fc receptor-mediated recycling and molecular weight increases that reduce the renal clearance. The phenomenon was demonstrated with interleukin-10 Fc-fusion proteins in mice at pharmacologically active doses. Future drug designs using Fc as a half-life extension approach for cytokines need to consider target expression and its effect on pharmacokinetics at relevant doses.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Interleukine-10 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Drug Metab Dispos Sujet du journal: FARMACOLOGIA Année: 2022 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Interleukine-10 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Drug Metab Dispos Sujet du journal: FARMACOLOGIA Année: 2022 Type de document: Article
...